TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00564733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging biomarker analysis
Description: Correlative studies
Study: NCT00138554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg qd
Study: NCT05021718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: Back and hip strengthening exercises. The intensity of exercises was based on the exercise tolerance and pain thresholds of the individual subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological therapy
Description: Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot compression
Description: Hot moist compression from week 4 to week 6.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activities to daily living instructions
Description: * Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities to daily living instructions
Description: * Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position.
Study: NCT02186626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4Δ30 Vaccine
Description: WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered by subcutaneous injection in the deltoid region of the upper arm.
Study: NCT02657265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpineJack system
Description: Spine fracture management for traumatic vertebral compression fracture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management
Description: Surgical corset according to measurement's impression, rigid corset with sternal support
Study: NCT00209105

Intervention type: DRUG
Intervention: DEX-CRF stimulation test
Description: 1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion

Intervention type: BEHAVIORAL
Intervention: Psychosocial stress induction
Description: Laboratory stress induction, no drug administration

Intervention type: PROCEDURE
Intervention: Brain imaging of sad mood , self-reference, reward
Description: Brain imaging

Intervention type: BEHAVIORAL
Intervention: Acoustic startle
Description: No drugs involved
Study: NCT03815734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: motor imagery during the postoperative immobilization period
Study: NCT02826772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918
Description: anti-tumor activity
Study: NCT03724214

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-hospital interventional care bundle
Description: The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: In-hospital interventional care bundle
Description: In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available.
Study: NCT02390128

Intervention type: OTHER
Intervention: observational only
Study: NCT01208116

Intervention type: OTHER
Intervention: Cardiovascular events
Description: * Coronary intervention~* Infarction~* Congestive heart failure~* Stroke~* Cardiac death
Study: NCT03836222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: MR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: MR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: MR tablet
Study: NCT02167854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJM716
Study: NCT03836222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: MR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: MR tablet
Study: NCT02167854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRASTUZUMAB
Study: NCT03414086

Intervention type: OTHER
Intervention: Healthy Control
Description: Ten healthy adult patients evaluating serum, PBMC's, and RNA.

Intervention type: OTHER
Intervention: Myositis in Remission
Description: Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
Study: NCT00936897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Ibandronate 150mg PO QM (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: denosumab 60mg SC Q6M (pre-filled syringe)
Study: NCT01296282

Intervention type: DEVICE
Intervention: Medronics CRT Optivol Impedance Measurement
Description: Pacemaker

Intervention type: DEVICE
Intervention: External Thoracic Impedance Measurement
Study: NCT00662623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-PAP
Description: Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (Standard Care)
Description: Pre-determined clinic visits and telephone support
Study: NCT00499421

Intervention type: PROCEDURE
Intervention: Computed Tomography (CT) Scan
Description: CT scan of the prostate three times a week, just before the delivery of radiation.
Study: NCT00127218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: any statin
Description: Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: any statin
Description: Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin
Description: long-acting niacin daily for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pill daily for 18 months
Study: NCT02752087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY900014
Description: Administered SC
Study: NCT02029014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAA closure system
Study: NCT03881423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: DEEP block to PTC 1-3
Study: NCT03836222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trental
Description: comparator tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trental
Description: comparator tablet
Study: NCT01323751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Description: Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
Study: NCT05563376

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Univentricular Hearts
Description: Prevention when factors are recognized
Study: NCT03423017

Intervention type: OTHER
Group type: OTHER
Intervention: Recording of data
Description: Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months

Intervention type: OTHER
Group type: OTHER
Intervention: Recording of data
Description: Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months

Intervention type: OTHER
Group type: OTHER
Intervention: Recording of data
Description: Recording during one hospitalization of 48 hours between birth and 2 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~* Respiratory rate, respiratory signs, stridor~* 24h holter-ECG~* 24h impedance pH-metry~* Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~* 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~* Succimetry procedure : at first visit only between birth and 2 months
Study: NCT03961841

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation with weekly 5Fu and oxaliplatin
Description: 5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative mFLOT
Description: Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX
Description: Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
Study: NCT03246724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg
Study: NCT02707445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
Study: NCT03426137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5mg Oxycodone in oral solution given every 3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5mg Oxycodone in oral solution given every 3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
Study: NCT03246724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg
Study: NCT03426137

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
Study: NCT00737763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
Study: NCT03190330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Description: Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg
Description: Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
Study: NCT03920579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study: NCT03246724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg
Study: NCT03920579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study: NCT02648100

Intervention type: OTHER
Intervention: biomarker study

Intervention type: OTHER
Intervention: biomarker study

Intervention type: OTHER
Intervention: biomarker study

Intervention type: OTHER
Intervention: biomarker study
Study: NCT03452982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sentinel node technique
Description: Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
Study: NCT00476385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropine
Description: subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
Study: NCT03309241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Single Dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Single Dose
Study: NCT05655416

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovenous chemical ablation with Trendelenburg's operation (eCAT)
Description: Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
Study: NCT00112840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779
Description: CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
Study: NCT04306770

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMUM programme
Description: OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content.
Study: NCT03920579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study: NCT04978922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine Learning: ML (Artificial Intelligence System)
Description: To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
Study: NCT01610414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A
Description: 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered IM in deltoid region of non-dominant arm
Study: NCT03180294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg XL
Description: By mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg XL
Description: By mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: By mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: By mouth
Study: NCT01926652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.